• A strategic move that further supports Mubadala’s efforts to advance the UAE’s life sciences sector
• Following the acquisition of four GlobalOne Healthcare Holding assets, this transaction represents the fifth strategic acquisition by KELIX bio since being acquired by Mubadala in March 2024

Abu Dhabi, 16 January 2025: KELIX bio, wholly owned by Mubadala Investment Company “Mubadala”, an Abu Dhabi sovereign investor, has completed the acquisition of DiabTec LLC, a subsidiary of Julphar. This acquisition strengthens Mubadala’s portfolio of biologicals, establishes its role in biomanufacturing across the MENA region, and supports its efforts to advance the UAE’s life sciences sector through local manufacturing.